14 nyvalda ledamöter till IVA

Kungl. Ingenjörsvetenskapsakademien, IVA, har utsett 14 nya ledamöter. Elva av dem finns vid svenska företag och lärosäten medan de andra tre är knutna till utländska institutioner.

Changeable proteins cause nerve disease

An incorrectly folded protein is one of the reasons behind the nerve disease ALS, according to new research. But the protein does not have structural errors all the time and only certain types contribute to the harmful protein accumulations that cause the ALS disease.

Stockholm-Uppsala life science cluster in brief

Stockholm-Uppsala evolves around the research at Karolinska Institutet and Uppsala University. Typical areas of research are protein research, neuroscience and cancer.

BMAs: Run your own business

After graduation you must decide: be an employee or start your own business. This is not really the situation for BMAs today, but a collaborative project between Swedish public actors and some companies aims to change that and make entrepreneurs of BMAs.

Diagnostics for personalized medicine

Per Matsson from Phadia anticipates changes in the standards for health care. Accordiing to him, expensive new drugs will create a market for more extensive diagnostics.

Cate Poulsen, Qiagen

Why are you going to Scanlab and Biotech Forum?

How to get the most out of the fair

From planning stage to handshake

"Partnering is an effective tool to get in touch with the decision makers high up in an organization's administration," says Camilla Huse Bondeson at Conlega. And according to her, rigorous planning is the way to succeed.

Ny professor startskott för LiU-satsning

May Griffith är ny professor i regenerativ medicin på Linköpings universitet och hennes kompetens blir startskottet för universitetets satsning på området.

EU-larmet om antibiotikaläget överdrivet

Enligt EU finns det bara 15 läkemedelskandidater i världen som kan bli avgörande för bekämpningen av multiresistenta bakterier. Siffran orsakade ett larm när rapporten presenterades i mitten av september. Men undersökningen tar bara hänsyn till substanser i klinisk fas.

Getinge får ny områdeschef

Med erfarenheter från bland annat Unilever, Orkla och Carlsberg blir Alex Meyers affärschef på området extended care inom Getingekoncernen.

50 får gå från Pfizer - vd slutar

Pfizers vd Niklas Prager lämnar bolaget i samband med en omorganisation som träder i kraft i april.

Major changes to the Q-Med board

The nomination committee wants to replace half of the existing board, including the current Chairman. An Extraordinary General Meeting will take place on February 4.

Swedish top scientists to EMBO

Two Swedish top scientists will have a really good chance to influence European life science research from now on. One is from the Karolinska Institutet, and one is from the University of Uppsala.

Teams up with leading dermatologist

Tripep has signed a letter of intent with a major Japanese specialty pharma company to bring their wound healing treatment to a big market.

Grant for development projects in Gothenburg

Seven research projects receive SEK 1 million to promote commercialization of early drug development and medical technology.

Pfizer lays a chunky bid on Wyeth

The merger of two pharma giants is the largest industry deal so far this year. Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at approximately $68 billion. The Boards of Directors of both companies have said yes to the deal that may lead to lay-offs of some 8,000 persons.

New member to Active board

The Election Committee of Active Biotech proposes a very experienced financial sector executive to join the company board. Five existing members are also to be re-elected at the AGM in May.

A smart company takes care of its best

Lundbeck didn't have to look far to find it's new international Director of Marketing. The talent was already in the house.

Researchers goes to the bottom of the brain

Swedish researchers have recently got new and deeper knowledge about the smallest part of the brain, the granule cells.

Almost 150 will leave Coloplast

The Danish medtech company Coloplast negotiates headcount reductions, with a total number of almost 150 employees.

Biovitrum sells UK part

Biovitrum will soon spin-out a British subsidary

Eli Lilly writes biotech fine history

The American biotech company Eli Lilly will pay US 1.415 billion to resolve allegations of off-label promotion of a dementia drug.

Abbott expands by acquisition

An acquisition gives Abbott a leadership position in another large and growing medical device segment.